Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
comparable to guideline study with acceptable restrictions

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1968
Report date:
1968

Materials and methods

Test guideline
Qualifier:
no guideline followed
Principles of method if other than guideline:
Female rats (10/dose) were fasted before dosing for 12 hours.
Animals were treated in concentrations of 800-5000 mg/kg bw/day via gavage.
Observation period was at least 48 hours.
GLP compliance:
no
Remarks:
study performed prior to implementation of GLP
Test type:
other: please refer to principles of method if other than guideline
Limit test:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
N-methyl-N-vinylacetamide
EC Number:
221-698-5
EC Name:
N-methyl-N-vinylacetamide
Cas Number:
3195-78-6
Molecular formula:
C5H9NO
IUPAC Name:
N-ethenyl-N-methylacetamide

Test animals

Species:
rat
Strain:
other: SPF Wistar K
Sex:
female
Details on test animals or test system and environmental conditions:
TEST ANIMALS

- Weight at study initiation: 80-106 g
- Fasting period before study: 12 hours before administration
- Diet: Standard-ALTROMIN R
- Water: tap water

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
water
Remarks:
10% aqueous solution
Doses:
800 mg/kg bw
1250 mg/kg bw
2000 mg/kg bw
3200 mg/kg bw
5000 mg/kg bw
No. of animals per sex per dose:
10 per dose (only females)
Details on study design:
- Duration of observation period following administration: 7 days

Results and discussion

Effect levels
Key result
Sex:
female
Dose descriptor:
LD50
Effect level:
1 760 mg/kg bw
Based on:
test mat.
Mortality:
Death occured within 100 min - 48 hours:
1250 mg/kg bw: 1/10
2000 mg/kg bw: 8/10
3200 mg/kg bw: 10/10
5000 mg/kg bw: 10/10
Clinical signs:
Ataxia, lateral/prone position and hyporeflexia

Applicant's summary and conclusion

Interpretation of results:
Category 4 based on GHS criteria